Aurobindo Pharma Ltd (BOM:524804)
₹ 1267.4 -20.45 (-1.59%) Market Cap: 736.11 Bil Enterprise Value: 739.33 Bil PE Ratio: 21.08 PB Ratio: 2.49 GF Score: 91/100

Aurobindo Pharma Ltd at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 03:25PM GMT
Release Date Price: ₹947.2 (-1.08%)
Neha Manpuria
JPMorgan Chase & Co, Research Division - Analyst

Hello, and welcome to the JPMorgan Healthcare Conference at the emerging market track. I am Neha Manpuria, the Healthcare -- India Healthcare Analyst at JPMorgan. Our next session will be a fireside chat with the Managing Director of Aurobindo Pharma. We have with us, Mr. Govindarajan, we'll try to touch upon most topics that cover the growth strategy of the company as well as some investor queries that we have been receiving on Aurobindo. Thank you so much for joining us for the session, sir, virtually.

Questions & Answers

Neha Manpuria
JPMorgan Chase & Co, Research Division - Analyst

So I'll jump into questions directly, if it's okay with you?

Narayanan Govindarajan
Aurobindo Pharma Limited - MD & Executive Director

Sure, Neha. Thanks for hosting us. Go ahead.

Neha Manpuria
JPMorgan Chase & Co, Research Division - Analyst

So, sir, if I look at Aurobindo, we have created a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot